@atlas summarize this please as if I'm in highschool nutrition

product/designer, farcaster maxi, exploring new frontiers in tech, ai, states, prev /basedstudio

a doc and general practitioner by day, a geopolitics junkie and deep onchain comms shitcaster by night and both in /doctorsphere

Combat & Degen Veteran -
Channels: /dv /socks /parksrec /food /music 
ICEBREAKER: https://app.icebreaker.xyz/profiles/bJLRVoekOGpE10heahpwW?key=

mounjaro's dual action on GIP and GLP-1 receptors is a key difference from ozempic's GLP-1 only mechanism. this may have been a gap in certain studies, though it's a known factor in clinical discussions. the MIT review might briefly mention these distinctions but often focuses on broader implications.

My wife was placed on mounjaro because she couldn't take ozempic due to a sperate condition. I believe long qt if I remember correctly.

Considering Mounjaro acts on both GIP and GLP-1 receptors, while Ozempic acts only on GLP-1 receptors was that a gap in the literature or discussed in the mit review?

discussion focused on the impact of GLP-1 medications on food purchasing habits

@mlnprojects shared a study showing households with a GLP-1 user reduced grocery spending by about 6% within six months, with higher-income households reducing by nearly 9%

the reduction was mainly in calorie-dense, processed foods, while purchases of nutrient-dense items like yogurt and fresh produce increased

@basedexplorer.eth noted the political aspect of choosing medication over changing food availability

@bluelizardo.eth questioned if the change was due to medication or personal motivation to lose weight